Developer docs
API playgroundTry for free, no card

Search company profiles

EvE Bio

Full company profile

uuid000cr7v

Namestring
EvE Bio
Legal namestring
EvE Bio, LLC
Websiteurl
evebio.org
Company typeenum
Private
Founded yearint
2023
Descriptiontext

EvE Bio is a non-profit Focused Research Organization (FRO) founded in 2023 in Durham, North Carolina, operating under Convergent Research with philanthropic support from Schmidt Futures, Founders Pledge, and Lyda Hill Philanthropies. The company systematically maps the pharmome by profiling libraries of small-molecule drugs against hundreds of druggable human proteins — nuclear receptors, 7-transmembrane receptors, and kinases — using a proprietary two-phase quantitative high-throughput screening process: a 3-concentration primary screen followed by 11-point concentration-response profiling with four-parameter logistic curve fitting. As of June 2026 (Data Release #12), the dataset comprises 648,208 rigorously confirmed drug-target interactions across 256 validated targets and 1,397 compounds, described as the largest public resource of its kind.

The core product is the Pharmome Mapping Dataset, distributed through four channels: a free interactive Data Explorer web app, downloadable data packages, programmatic access on Hugging Face, and integration into DrugBank's commercial drug discovery intelligence platform (where DrugBank also serves as commercial sponsor). The dataset is offered under a Creative Commons CC BY-NC-SA 4.0 license for non-commercial use, with alternative commercial licensing available on direct inquiry. Customer segments span pharmaceutical and biotech researchers (off-target liability assessment, drug repurposing), AI/ML researchers in drug discovery (training and validation data for models such as FutureHouse's ether0), academic researchers, and disease-specific AI initiatives (notably OpenAI Foundation's AI for Alzheimer's program on allosteric modulators). Revenue is generated primarily through philanthropic grants and a single named commercial sponsor rather than transactional software sales.

Short descriptiontext

EvE Bio is a non-profit Focused Research Organization that systematically maps drug-target interactions across hundreds of human proteins, producing the largest public pharmome-mapping dataset for pharma researchers, AI/ML drug-discovery teams, and academic users.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmome mapping datasets, drug target interaction data, high throughput screening, pharmacology research data, drug discovery intelligence
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical Laboratories621511
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Prepackaged Software7372
Product category
Drug Discovery Data and Analytics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Public Data Access (Non-profit / Open Science)
TypeData Monetisation
Description

EvE Bio is a non-profit Focused Research Organization (FRO). Primary outputs are freely available under Creative Commons CC BY-NC-SA 4.0 license. Funded by philanthropic support from Convergent Research, Eric and Wendy Schmidt/Schmidt Futures, Founders Pledge, and Lyda Hill Philanthropies.

evebio.org
2Commercial Data Licensing
TypeLicensing Royalties
Description

Alternative licensing options including commercial terms are available by contacting info@evebio.org. The data is also integrated into DrugBank's commercial platform, with DrugBank acknowledged as EvE's commercial sponsor.

evebio.org
3Partnership Integration Revenue
TypeData Monetisation
Description

Integration with commercial platforms (DrugBank) likely generates revenue through co-distribution arrangements. DrugBank is listed as a commercial sponsor.

evebio.org
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Pricing details1 tier
1Free public access dataset
ModelFreemiumBilling cadencePay-as-you-go
Notes

Pharmaceutical data provided for viewing or downloading on the EvE Bio website is licensed to the public under Creative Commons CC BY-NC-SA 4.0 license. Alternative licensing options, including commercial terms, are available by contacting info@evebio.org.

data.evebio.org
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

EvE Bio generates a systematic pharmome-mapping dataset by quantitatively screening drug libraries across hundreds of druggable human proteins. It makes the resulting drug-target interaction data available through an interactive Data Explorer, downloadable files, and a Hugging Face dataset, with commercial licensing available by direct inquiry.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

EvE Bio is a Focused Research Organization that produces the world's largest pharmome-mapping dataset—a comprehensive collection of drug-target interaction data. The core offering is the Pharmome Mapping Dataset containing 648,208 interactions across 256 targets and 1,397 compounds. This data is made accessible through multiple channels: the interactive EvE Bio Data Explorer web application for visual exploration and analysis, downloadable Data Packages for offline use, and the Hugging Face Dataset for programmatic ML access. The company generates data in-house at its North Carolina laboratory using quantitative high-throughput screening with two phases (3-point screening followed by 11-point profiling), providing rigorous confirmation of inactive compounds and quantified potency for active compounds. Key applications enabled by the dataset include off-target liability assessment, drug repurposing identification, and training/validation data for AI and machine learning models in drug discovery.

Product and service3 records
1Pharmome Mapping Dataset
CategoryPharmome mapping dataset
Description

A structured dataset of drug-target activity covering 1,397 compounds and 256 screened targets, including nuclear receptors, 7TM receptors, and kinases. As of Data Release #12, it contains 648,208 screened interactions and records a result for every compound-target combination.

2EvE Bio Data Explorer
CategoryInteractive drug discovery analytics
Description

An interactive web application that lets researchers explore pharmome-mapping results, visualize dose-response curves, and filter by target class, target, compound, mode, mechanism, and assay.

3Data Downloads
CategoryDownloadable pharmacology data
Description

Downloadable summary results, computational results, compound and target metadata, assay metadata, observed data points, and methods documentation for offline analysis. Public files are offered under the Creative Commons CC BY-NC-SA 4.0 license.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-08
Description

EvE Bio partnered with OpenAI Foundation on their 'AI for Alzheimer's' initiative. EvE will produce focused pharmacology datasets needed for AI models to learn allosteric modulator design, with dozens of Alzheimer's-relevant targets in their existing repertoire. The partnership aims to address the data gap that makes designing allosteric modulators difficult for AI models.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

EvE Bio and DrugBank partnered to integrate EvE's pharmome-mapping dataset — 385,572 rigorously confirmed drug-target interactions across 1,397 compounds and 159 validated targets — into DrugBank's drug discovery intelligence platform. This integration enables applications such as off-target liability assessment, drug repurposing, and enriched cheminformatics analysis. DrugBank is also acknowledged as EvE's commercial sponsor.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-18
Description

EvE Bio's pharmome dataset is accessible programmatically on Hugging Face via the python datasets library, enabling ML researchers to integrate the data directly into their machine learning workflows. The integration was highlighted as making the data accessible to researchers in an actionable format.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

FutureHouse used EvE Bio's data for training and validation of ether0, their chemistry-specific reasoning model. Their work demonstrated that domain-specific AI development can be surprisingly data efficient, validating EvE's vision of providing experimental ground truth for AI model development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Insitro is an AI/ML-driven drug discovery company that combines high-throughput biology with machine learning models to predict drug behavior. It shares EvE Bio's philosophy of using systematic experimental data to train AI for pharma, but operates as a for-profit therapeutics company.

TypeDirect peer
Description

DrugBank is a leading drug knowledge platform providing pharmaceutical and pharmacological data on drugs, targets, and pathways. It is both EvE Bio's primary commercial sponsor and distribution partner, integrating EvE's dataset into its enterprise platform—the most directly comparable company by product overlap and customer base.

TypeBroad incumbent
Description

Recursion is an AI-driven drug discovery company that combines high-throughput wet-lab biology with machine learning. While it pursues internal therapeutic programs rather than open data, its scale of experimental data generation and use of ML to drive drug discovery makes it a broader incumbent comparable to EvE's approach.

TypeEmerging player
Description

Atomwise applies AI to predict drug-target binding using structure-based models and has historically partnered with academic groups to generate experimental binding data. It overlaps with EvE Bio's mission of using ML for drug discovery but historically focused more on binding prediction than systematic experimental profiling.

TypeOthers
Description

Convergent Research is EvE Bio's parent organization—the Focused Research Organization (FRO) that incubates and funds ambitious, time-limited scientific projects like EvE. While not a direct competitor, it is the structural and funding peer that defines EvE's operating model and connects it to similar FROs in adjacent scientific domains.

6Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs (Alphabet-owned) applies DeepMind's AI to drug discovery, with significant investment in proprietary drug-target interaction data and modeling. It represents a much larger, well-capitalized player working on the same problem EvE addresses—generating systematic molecular interaction data for AI-driven drug design.

7ChEMBL
TypeDirect peer
Description

ChEMBL is a manually curated database of bioactive molecules with drug-like properties, maintained by EMBL-EBI. It is one of the largest public resources for drug-target bioactivity data, directly comparable to EvE's pharmome-mapping dataset in scope, public availability, and use cases.

TypeDirect peer
Description

PharmGKB is a pharmacogenomics knowledge resource that collects, encodes, and disseminates knowledge about the impact of human genetic variation on drug response. While more focused on clinical pharmacogenomics, it shares EvE Bio's mission of building public, structured pharmacology data for the research community.

9PubChem
TypeDirect peer
Description

PubChem is the NIH's open chemistry database aggregating chemical structures, bioactivity assay results, and target information. Like EvE, it serves as a foundational public data resource for drug discovery and cheminformatics research.

TypeDirect peer
Description

Open Targets is a public-private partnership that builds systematic target identification and validation datasets for drug discovery. Like EvE Bio, it generates open-access, structured experimental data to support target prioritization, making it a direct peer in the open target-identification data space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EvE Bio

Drug Discovery Data and Analyticsevebio.org

EvE Bio is a non-profit Focused Research Organization that systematically maps drug-target interactions across hundreds of human proteins, producing the largest public pharmome-mapping dataset for pharma researchers, AI/ML drug-discovery teams, and academic users.

What EvE Bio does

EvE Bio is a non-profit Focused Research Organization (FRO) founded in 2023 in Durham, North Carolina, operating under Convergent Research with philanthropic support from Schmidt Futures, Founders Pledge, and Lyda Hill Philanthropies. The company systematically maps the pharmome by profiling libraries of small-molecule drugs against hundreds of druggable human proteins — nuclear receptors, 7-transmembrane receptors, and kinases — using a proprietary two-phase quantitative high-throughput screening process: a 3-concentration primary screen followed by 11-point concentration-response profiling with four-parameter logistic curve fitting. As of June 2026 (Data Release #12), the dataset comprises 648,208 rigorously confirmed drug-target interactions across 256 validated targets and 1,397 compounds, described as the largest public resource of its kind.

The core product is the Pharmome Mapping Dataset, distributed through four channels: a free interactive Data Explorer web app, downloadable data packages, programmatic access on Hugging Face, and integration into DrugBank's commercial drug discovery intelligence platform (where DrugBank also serves as commercial sponsor). The dataset is offered under a Creative Commons CC BY-NC-SA 4.0 license for non-commercial use, with alternative commercial licensing available on direct inquiry. Customer segments span pharmaceutical and biotech researchers (off-target liability assessment, drug repurposing), AI/ML researchers in drug discovery (training and validation data for models such as FutureHouse's ether0), academic researchers, and disease-specific AI initiatives (notably OpenAI Foundation's AI for Alzheimer's program on allosteric modulators). Revenue is generated primarily through philanthropic grants and a single named commercial sponsor rather than transactional software sales.

EvE Bio firmographics

Firmographics
Name
EvE Bio
Legal name
EvE Bio, LLC
Website
https://evebio.org
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
EvE Bio is a non-profit Focused Research Organization that systematically maps drug-target interactions across hundreds of human proteins, producing the largest public pharmome-mapping dataset for pharma researchers, AI/ML drug-discovery teams, and academic users.
Ownership category
akta.pro rank

EvE Bio industry classification

Industry
Product category
Drug Discovery Data and Analytics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Pharmome mapping datasets
  • Drug target interaction data
  • High throughput screening
  • Pharmacology research data
  • Drug discovery intelligence

Where EvE Bio is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

EvE Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Public Data Access (Non-profit / Open Science): EvE Bio is a non-profit Focused Research Organization (FRO). Primary outputs are freely available under Creative Commons CC BY-NC-SA 4.0 license. Funded by philanthropic support from Convergent Research, Eric and Wendy Schmidt/Schmidt Futures, Founders Pledge, and Lyda Hill Philanthropies.
  2. Commercial Data Licensing: Alternative licensing options including commercial terms are available by contacting info@evebio.org. The data is also integrated into DrugBank's commercial platform, with DrugBank acknowledged as EvE's commercial sponsor.
  3. Partnership Integration Revenue: Integration with commercial platforms (DrugBank) likely generates revenue through co-distribution arrangements. DrugBank is listed as a commercial sponsor.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goFree public access dataset

Go-to-market motion1 record

Distribution channels5 records

Marketing channels10 records

EvE Bio product offering

Product offering

Core offering

EvE Bio generates a systematic pharmome-mapping dataset by quantitatively screening drug libraries across hundreds of druggable human proteins. It makes the resulting drug-target interaction data available through an interactive Data Explorer, downloadable files, and a Hugging Face dataset, with commercial licensing available by direct inquiry.

Product overview

EvE Bio is a Focused Research Organization that produces the world's largest pharmome-mapping dataset—a comprehensive collection of drug-target interaction data. The core offering is the Pharmome Mapping Dataset containing 648,208 interactions across 256 targets and 1,397 compounds. This data is made accessible through multiple channels: the interactive EvE Bio Data Explorer web application for visual exploration and analysis, downloadable Data Packages for offline use, and the Hugging Face Dataset for programmatic ML access. The company generates data in-house at its North Carolina laboratory using quantitative high-throughput screening with two phases (3-point screening followed by 11-point profiling), providing rigorous confirmation of inactive compounds and quantified potency for active compounds. Key applications enabled by the dataset include off-target liability assessment, drug repurposing identification, and training/validation data for AI and machine learning models in drug discovery.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmome Mapping Dataset A structured dataset of drug-target activity covering 1,397 compounds and 256 screened targets, including nuclear receptors, 7TM receptors, and kinases. As of Data Release #12, it contains 648,208 screened interactions and records a result for every compound-target combination.
  • EvE Bio Data Explorer An interactive web application that lets researchers explore pharmome-mapping results, visualize dose-response curves, and filter by target class, target, compound, mode, mechanism, and assay.
  • Data Downloads Downloadable summary results, computational results, compound and target metadata, assay metadata, observed data points, and methods documentation for offline analysis. Public files are offered under the Creative Commons CC BY-NC-SA 4.0 license.

Companies that use EvE Bio

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles5 records

EvE Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature5 records

EvE Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • OpenAI FoundationcoreStrategic or Co-development Partner · 8 April 2026EvE Bio partnered with OpenAI Foundation on their 'AI for Alzheimer's' initiative. EvE will produce focused pharmacology datasets needed for AI models to learn allosteric modulator design, with dozens of Alzheimer's-relevant targets in their existing repertoire. The partnership aims to address the data gap that makes designing allosteric modulators difficult for AI models.
  • DrugBankcoreStrategic or Co-development Partner · 18 November 2025EvE Bio and DrugBank partnered to integrate EvE's pharmome-mapping dataset — 385,572 rigorously confirmed drug-target interactions across 1,397 compounds and 159 validated targets — into DrugBank's drug discovery intelligence platform. This integration enables applications such as off-target liability assessment, drug repurposing, and enriched cheminformatics analysis. DrugBank is also acknowledged as EvE's commercial sponsor.
  • Hugging FacecoreTechnology or Integration · 18 November 2025EvE Bio's pharmome dataset is accessible programmatically on Hugging Face via the python datasets library, enabling ML researchers to integrate the data directly into their machine learning workflows. The integration was highlighted as making the data accessible to researchers in an actionable format.
  • FutureHouseflagshipStrategic or Co-development Partner · 18 November 2025FutureHouse used EvE Bio's data for training and validation of ether0, their chemistry-specific reasoning model. Their work demonstrated that domain-specific AI development can be surprisingly data efficient, validating EvE's vision of providing experimental ground truth for AI model development.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

EvE Bio competitors and assessment

Company assessment

Broad incumbents

  • Insitro: Insitro is an AI/ML-driven drug discovery company that combines high-throughput biology with machine learning models to predict drug behavior. It shares EvE Bio's philosophy of using systematic experimental data to train AI for pharma, but operates as a for-profit therapeutics company.
  • Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company that combines high-throughput wet-lab biology with machine learning. While it pursues internal therapeutic programs rather than open data, its scale of experimental data generation and use of ML to drive drug discovery makes it a broader incumbent comparable to EvE's approach.
  • Isomorphic Labs: Isomorphic Labs (Alphabet-owned) applies DeepMind's AI to drug discovery, with significant investment in proprietary drug-target interaction data and modeling. It represents a much larger, well-capitalized player working on the same problem EvE addresses—generating systematic molecular interaction data for AI-driven drug design.

Direct peers

  • DrugBank: DrugBank is a leading drug knowledge platform providing pharmaceutical and pharmacological data on drugs, targets, and pathways. It is both EvE Bio's primary commercial sponsor and distribution partner, integrating EvE's dataset into its enterprise platform—the most directly comparable company by product overlap and customer base.
  • ChEMBL: ChEMBL is a manually curated database of bioactive molecules with drug-like properties, maintained by EMBL-EBI. It is one of the largest public resources for drug-target bioactivity data, directly comparable to EvE's pharmome-mapping dataset in scope, public availability, and use cases.
  • PharmGKB: PharmGKB is a pharmacogenomics knowledge resource that collects, encodes, and disseminates knowledge about the impact of human genetic variation on drug response. While more focused on clinical pharmacogenomics, it shares EvE Bio's mission of building public, structured pharmacology data for the research community.
  • PubChem: PubChem is the NIH's open chemistry database aggregating chemical structures, bioactivity assay results, and target information. Like EvE, it serves as a foundational public data resource for drug discovery and cheminformatics research.
  • Open Targets: Open Targets is a public-private partnership that builds systematic target identification and validation datasets for drug discovery. Like EvE Bio, it generates open-access, structured experimental data to support target prioritization, making it a direct peer in the open target-identification data space.

Emerging players

  • Atomwise: Atomwise applies AI to predict drug-target binding using structure-based models and has historically partnered with academic groups to generate experimental binding data. It overlaps with EvE Bio's mission of using ML for drug discovery but historically focused more on binding prediction than systematic experimental profiling.

Others

  • Convergent Research: Convergent Research is EvE Bio's parent organization—the Focused Research Organization (FRO) that incubates and funds ambitious, time-limited scientific projects like EvE. While not a direct competitor, it is the structural and funding peer that defines EvE's operating model and connects it to similar FROs in adjacent scientific domains.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

EvE Bio social profiles

Digital presence

EvE Bio compliance and trust

Trust signal

Compliance1 record

EvE Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EvE Bio leadership team

Management profile

Number of profiles

Profiles8 records

EvE Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EvE Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EvE Bio

What does EvE Bio do?

EvE Bio generates a systematic pharmome-mapping dataset by quantitatively screening drug libraries across hundreds of druggable human proteins. It makes the resulting drug-target interaction data available through an interactive Data Explorer, downloadable files, and a Hugging Face dataset, with commercial licensing available by direct inquiry.

Is EvE Bio a public or private company?

EvE Bio is a private company. It is classified as unknown and is currently operating.

When was EvE Bio founded?

EvE Bio was founded in 2023. It employs 11 to 50 people.

Where is EvE Bio based?

EvE Bio is headquartered in Durham, United States, in the North America region.

How does EvE Bio make money?

Three revenue lines are on record. Public Data Access (Non-profit / Open Science) is the primary driver. The others are commercial Data Licensing and partnership Integration Revenue.

Who are EvE Bio's main competitors?

Broad incumbents on record are Insitro, Recursion Pharmaceuticals and Isomorphic Labs. Direct peers are DrugBank, ChEMBL, PharmGKB, PubChem and Open Targets. Atomwise is listed as an emerging player. Convergent Research is listed as an others.

Does EvE Bio have an API?

No public API is recorded for EvE Bio.

What industry is EvE Bio in?

EvE Bio's product category is Drug Discovery Data and Analytics. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals